News
Public · Published
Needham maintains Hims & Hers Health at Buy, lowers price target to $32 from $42
Needham kept its Buy rating on Hims & Hers Health but lowered its price target to $32 from $42, a 23.8% decrease. The new target implies 39.5% upside from the stock's Nov. 9 closing price of $22.94.
Published:
Updated:
What happened
Needham kept its Buy rating on Hims & Hers Health but lowered its price target to $32 from $42, a 23.8% decrease. The new target implies 39.5% upside from the stock’s Nov. 9 closing price of $22.94.
Confirmed
Global impact / market context
The lower target signals that Needham sees less potential value than before, even while it still rates the shares Buy. If investors respond by revising their expectations, the company’s share price and its ability to raise money through stock sales could be affected.
Analyst inference
The article reports one analyst’s rating and target change, not a change in Hims & Hers Health’s reported business results. The stated upside compares the target with the Nov. 9 close; it is an estimate, not a promised return or forecast outcome.
Confirmed
What to watch
- Watch for Needham’s later rating or target changes, which would show whether the analyst’s view shifts again; no further recommendation is reported in this article. Analyst inference
- Compare future company updates on revenue, costs, and cash available with the expectations implied by analyst targets; the supplied article provides no operating results. Analyst inference
- The $32 target is an analyst estimate, not a guaranteed price. Any investor decision based on it would depend on their own goals and risk tolerance. Confirmed
Evidence
- Original source link unavailable